Hosted by the European Organisation for Research and Treatment of Cancer (EORTC), the National Cancer Institute (NCI) and the American Association for Cancer Research (AACR), the 2016 Symposium will bring together academics, scientists and pharmaceutical industry representatives from across the globe to discuss the latest innovations in drug development, target selection and the impact of new discoveries in molecular biology.

Building on the success and focus of previous highly acclaimed symposiums, this drug development and translational research meeting, focusing on preclinical and phase I studies, will enable delegates to have in-depth scientific discussions on the latest developments in targets and drugs.